Pol Przegl Chir. 2026 Jan 27;98(2):13-18. doi: 10.5604/01.3001.0055.5916.
ABSTRACT
<b>Introduction:</b> Colorectal cancer (CRC) is the second most common cancer worldwide. Much attention has recently been paid to the epigenetic features of CRC. Homologous recombination repair (HRR) is a biochemical pathway that plays a crucial role in maintaining genome integrity through the repair of double-strand breaks (DBS). <i>RAD51</i> recombinase is widely considered a key enzyme in HRR. Genome-wide single nucleotide polymorphisms (SNPs) are a significant type of genetic variation.<b>Aim:</b> The aim of this study was to assess the association between the occurrence of individual genotypes/alleles of the <i>RAD51</i> 172G/T polymorphism (rs1801321) and the risk of CRC.<b>Materials and methods:</b> The material used for DNA isolation was peripheral blood from patients at the Department of General and Colorectal Surgery, Medical University of Lodz. The study recruited patients (n = 188) with histologically confirmed colorectal cancer. The control group consisted of undiagnosed individuals (n = 200), matched for age and gender, without a family history of cancer among first-degree relatives.<b>Results:</b> No statistically significant association was found between the frequency of the assessed alleles/genotypes and the presence of CRC. The analysis also showed that the 127G/T variant of the RAD51 gene was not statistically significantly associated with the development of colorectal cancer.<b>Discussion:</b> The 127G/T polymorphism of the <i>RAD51</i> gene appears to be an unpromising marker for colorectal cancer. However, new observations regarding the variant in the distal promoter may open up prospects for future research on molecular markers.<b>Conclusions:</b> The study results indicate no association between the <i>RAD51</i> 172G/T polymorphism and the risk of CRC. Therefore, there is a need for further research in the area of selected polymorphisms in CRC.
PMID:42178953 | DOI:10.5604/01.3001.0055.5916